The PROSPER study showed that patients treated with enzalutamide lived longer than patients treated with placebo. But do patients’ traits affect the how people respond to treatment? This plain language summary published in Future Oncology provides an overview of a study examining this question.
Read the full article here.
The original article on which this summary is based is called ‘Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region’ and was originally published in the journal European Journal of Cancer. The original article can be read here.